ICML 2019 | Recent publication on the impact of response to lymphodepletion on PFS in NHL

Alexandre Hirayama

Alexandre Hirayama, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses his recent research into the impact of response to lymphodepletion on PFS in non-Hodgkin lymphoma (NHL). This revealed that LDH, MCP-1, and IL-7 are independently associated with PFS in patients with aggressive NHL after CD19 CAR T-cell therapy. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  
Similar topics
Related videos
Venetoclax monotherapy for relapsed/refractory Waldenström’s macroglobulinemia
Jorge Castillo
Waldenström's PFS unaffected by ibrutinib dose reduction, for now
Jorge Castillo
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
Waldenström’s macroglobulinemia: a link between institution visited and survival
Stephen Ansell
1:15
R/R DLBCL challanges: novel therapeutics
Jarrod Longcor
Lymphoma, Non-Hodgkin Lymphoma
CAR-T
ICML 2019
Interview
20th June 2019
More from Alexandre Hirayama
Durable responses after CD19 CAR-T plus ibrutinib in CLL
Cami-T in R/R cHL: analysis of clinical determinants of safety and efficacy
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals